Peptech Limited Appoints Chief Medical Officer In Preparation for Advancing to Phase II Patient Trials
6/6/2007 5:13:11 PM
Sydney, 6 June 2007: Peptech Limited (ASX: PTD, AIM: PTDx) today announced the appointment of Dr. David Fuller as Chief Medical Officer. The appointment is a crucial step in Peptech’s plans to rapidly advance the clinical trial program of its lead anti-inflammatory compound, PN0621.
comments powered by